Diabetes insipidus (DI) is a rare medical condition that disrupts the body's ability to regulate water, resulting in excessive thirst and an unusually high volume of urine. This condition affects the kidneys' ability to concentrate urine and causes individuals to produce between 3 and 20 quarts of dilute, colourless urine daily, compared to an average of 1 to 2 quarts. It is pertinent to note that DI is not related to diabetes mellitus, which disrupts the body's insulin production.

Types Of Diabetes Insipidus

This condition results from damage to the hypothalamus or pituitary gland, which impairs the production or release of vasopressin, a hormone responsible for water retention. When vasopressin levels are inadequate, the kidneys fail to conserve water, leading to excessive urination. It can result from Brain injuries or surgeries, tumours, infections or inflammation and aneurysms.

Nephrogenic Diabetes Insipidus

This type occurs when the kidneys fail to respond to vasopressin, causing excessive fluid loss. Common triggers include chronic kidney disease, and electrolyte imbalances, such as high calcium or low potassium levels. Additionally, medications like lithium

and urinary tract blockages can also cause Nephrogenic DI.

Gestational Diabetes Insipidus

A rare condition seen only during pregnancy, this occurs when the placenta produces an enzyme that breaks down vasopressin or increases prostaglandin levels, reducing kidney sensitivity to the hormone. Symptoms of this are usually mild and often resolve postpartum but can recur in future pregnancies.

Symptoms And Warning Signs

• Severe thirst, often leading to the consumption of over a gallon of water daily
• Frequent urination (polyuria), sometimes exceeding 20 quarts per day
• Nighttime urination and bed-wetting
• Weakness, muscle pain, and preference for cold drinks

In severe cases, dehydration may develop, manifesting as fatigue, dizziness, dry mouth, confusion, nausea, or fainting. Infants and children with DI may exhibit crankiness, poor feeding, slow growth, fever, or vomiting.

Causes And Risk Factors

DI stems from issues with vasopressin production or response. Central DI arises from damage to brain structures, while nephrogenic DI relates to kidney dysfunction. Risk factors include:

- Genetic mutations affecting water regulation

- Certain medications like diuretics or lithium

- Metabolic disorders that alter calcium or potassium levels

- Brain injuries or surgeries

Diagnosis And Testing

Diagnosing DI involves a combination of medical history, physical exams, and specialized tests:

- Urinalysis: Evaluates urine concentration and glucose levels to distinguish DI from diabetes mellitus.

- Blood tests: Check electrolyte, glucose, and vasopressin levels.

- Water deprivation test: Measures changes in weight, blood sodium, and urine concentration during fluid restriction.

- MRI: Detects abnormalities in the hypothalamus or pituitary gland.

- Genetic screening: Identifies inherited risk factors.

Although DI is rare, affecting about 1 in 25,000 people, early diagnosis and targeted treatment can significantly improve quality of life. Researchers continue to explore its causes and treatments to better support those living with this challenging condition.

With the increasing use of smartphones, laptops and other digital devices, neck pain and back discomfort are becoming common concerns among people of different age groups. Long working hours, improper sitting positions and excessive screen time are putting additional pressure on the spine. What may begin as mild stiffness in the neck or shoulders can gradually develop into persistent discomfort if ignored.

Poor posture and prolonged screen use are among the common lifestyle factors contributing to neck and back pain.

Many people complain of neck stiffness or back pain despite not being involved in physically demanding activities. On examining their daily routine, we often find that they spend several hours working on computers or looking at their mobile phones without taking adequate breaks. Maintaining the same posture for extended periods can put unnecessary stress on the spine.

The spine is a complex structure made up of vertebrae, intervertebral discs, joints, ligaments and muscles. It supports the body, helps maintain balance and allows movement. However, prolonged sitting and incorrect posture can affect the normal functioning of these structures.

One of the growing concerns associated with digital device usage is ‘text neck’, a term commonly used to describe neck pain and discomfort linked to repeatedly looking down at smartphones and tablets. When the head moves forward from its natural position, the muscles of the neck and shoulders have to work harder to support it. Over time, this may lead to stiffness, muscle fatigue and recurring pain.

Children and teenagers are also vulnerable to posture-related problems because of extended screen time, online learning and gaming. Encouraging them to take regular breaks and participate in outdoor activities can help promote better musculoskeletal health.

The effects of an inactive lifestyle extend beyond the spine. Reduced physical activity can contribute to weight gain, poor muscle strength and an increased risk of metabolic and cardiovascular health problems. Regular movement is therefore important not only for spinal health but also for overall well-being.

Simple Lifestyle Changes Can Make a Difference

Preventing posture-related pain does not necessarily require complicated exercise routines. Small changes in everyday habits can help reduce strain on the neck and back.

Taking short breaks during working hours instead of remaining seated continuously. Standing up, walking around or performing gentle stretches every 30 minutes can help reduce prolonged static loading on the spine.

Workstation ergonomics also plays an important role. People should keep their feet comfortably supported on the floor, maintain a relaxed shoulder position and avoid bending their neck forward for extended periods. The computer screen should be positioned at a comfortable viewing height, while laptop users can consider an external keyboard and mouse to improve their working posture.

Regular physical activity can further support spinal health. Exercises such as bridges, planks and bird dogs can help strengthen the muscles that support the spine when performed correctly. Walking, swimming and cycling are also useful ways to remain active. The World Health Organization recommends that adults undertake at least 150 minutes of moderate-intensity physical activity each week.

People with obesity, diabetes or a family history of spinal disorders should pay particular attention to their daily activity levels and seek medical advice when necessary. Parents should also encourage children to balance screen time with physical activity and healthy movement habits.

When Should You Consult a Specialist?

Occasional discomfort that improves with movement or a change in posture may not necessarily indicate a serious problem. However, persistent or worsening pain should not be ignored.

Consulting a doctor if neck or back pain continues for several weeks, radiates into the arms or legs, or is accompanied by tingling, numbness or muscle weakness. Pain associated with fever or unexplained weight loss also requires prompt medical evaluation.

Do not rely on painkillers for prolonged periods without professional guidance. Pain relief alone may not address the underlying cause, making an appropriate assessment important when symptoms persist.

Most cases of neck and back pain do not require surgery. Many can improve with appropriate treatment, physical activity and changes in daily habits. The important thing is to identify the cause of the pain and avoid ignoring recurring symptoms

As digital devices become an essential part of modern life, protecting spinal health requires greater awareness of posture, regular movement and healthy screen habits. Simple preventive measures adopted today can help people maintain better mobility and comfort in the long run.

(By Dr. Lalit Kumar, Director Consultant, Orthopaedics, Joint Replacement and Spine Surgeon at Shalby International Hospitals, Gurugram)

Beyond weight loss and diabetes control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with schizophrenia and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.

The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.

What Did the Study Find?

Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor

Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.

The researchers found that people taking GLP-1 drugs were:

• 24% less likely to require psychiatric hospitalization than those not taking any of the compared diabetes medications.
• 18% less likely to require psychiatric hospitalization than those taking DPP-4 inhibitors.
• 17% less likely to require psychiatric hospitalization than those taking SGLT2 inhibitors.

GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:

• 29% less likely to require emergency care than those not taking any of the compared diabetes medications.
• 13% less likely than those taking DPP-4 inhibitors.
• 20% less likely than those taking SGLT2 inhibitors.

Further, when the researchers analyzed individual drugs, the association was observed with semaglutide, liraglutide, and tirzepatide, but not dulaglutide.

GLP-1 Drugs Not Primary Treatment for Schizophrenia

Read More: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?

The researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.

They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.

Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.

“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.

They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.

Why Is Type 2 Diabetes More Common in People With Schizophrenia?

Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.

Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.

Several factors may contribute to this increased risk, including:

• Obesity
• High cholesterol and other abnormal blood lipid levels
• Elevated blood sugar
• Smoking
• Unhealthy diet
• Physical inactivity
• Poor sleep
• Stress

Could GLP-1 Drugs Help Address Both Conditions?

GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.

However, whether these medications directly improve psychiatric outcomes remains uncertain.

The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.

Originally developed to treat type 2 diabetes and obesity, GLP-1 receptor agonists have shown benefits beyond blood sugar control and weight loss, including for cardiovascular and kidney health.

Some women, particularly those with polyendocrine metabolic ovarian syndrome (PMOS), formerly known

as PCOS, have reported conceiving after taking these medications.

Although GLP-1 drugs can support weight loss and improve metabolic health, evidence that they directly improve fertility remains limited.

Woman Says GLP-1 Drug Helped Her Conceive

For 30-year-old Ashlee Amborn, pregnancy was challenging. According to ABC News, she had PMOS, one functioning fallopian tube and half a uterus, which complicated her chances of conceiving naturally.

After years of fertility treatments, she conceived her first two children. Four months after her second child's birth, she became pregnant again.

Amborn said a GLP-1 drug prescribed to manage her PMOS symptoms, including inflammation and hormonal imbalances, helped her conceive. She became pregnant after taking the medication for a month.

"It was kind of these mixed emotions of, 'Holy cow, I'm pregnant,'" Amborn said. "I did this on my own without fertility treatment. All it took was a GLP-1."

Also read: Sorority Rush Sees Ozempic Trend: What Young Women Should Know Before Using GLP-1 Drugs

What Does Research Say?

A recent review published in the Journal of the Brazilian Reproduction Association (JBRA) Assisted Reproduction suggests a possible association between GLP-1 use and improved fertility outcomes in women with obesity and PMOS, particularly those also taking metformin, a medication used to manage blood sugar.

Weight loss and improved insulin sensitivity may support ovulation and reduce ovarian dysfunction. However, more research is needed to establish whether these medications improve pregnancy or live-birth rates.

Can GLP-1 Drugs Affect Ovulation?

Dr. Jacinta Anyaoku, a physician at Maven Clinic specializing in obesity and women's health in midlife, told ABC News that research has not established a direct link between GLP-1 use and ovulation rates, although she has observed potential benefits among her patients.

"When you lose weight, your inflammation goes down," Anyaoku said. "It actually can help with improving your rate of ovulation. Your egg quality could potentially improve if you have reduced inflammation, and so these are all potential effects that come with GLP-1 use."

Sharrón L. Manuel, a board-certified OB/GYN and reproductive endocrinology specialist at HRC Fertility, attributes the reported "Ozempic Baby Boom" largely to weight loss and improved metabolic health, which may help restore ovulation.

Excess body weight can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contribute to insulin resistance and affect egg and uterine lining quality.

Manuel also points to preliminary research suggesting GLP-1 drugs may influence reproductive function through hormonal regulation, reduced inflammation and improved insulin sensitivity. However, preclinical findings involving ovarian function and endometrial receptivity require further investigation in humans.

Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth

Can GLP-1 Drugs Be Used During Pregnancy?

GLP-1 drugs should not be used during pregnancy. Women planning to conceive should consult their healthcare professional about stopping treatment. For semaglutide, prescribing guidance recommends discontinuation at least two months before a planned pregnancy.

Women should also seek medical advice about using these medications while breastfeeding.

The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss the risks, benefits and timing with their healthcare professional, particularly if they plan to conceive.

What About Birth Control?

Tirzepatide, sold under the brand names Mounjaro and Zepbound, can affect oral contraceptive absorption. Its prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after each dose increase.